Skip to main content

Table 3 Tumour characteristics and treatment in NASH vs non-NASH-HCC

From: Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma

Characteristics NASH - HCC Non-NASH - HCC P
(n = 45) (n = 1074)
(n [%]) (n [%])
Histological confirmation of HCC 39 (86.7) 939 (87.4) 1.000
Grading    
  G1 9 (20) 233 (21.7) 1.000
  G2 20 (44.4) 438 (40.8) 0.781
  G3 6 (13.3) 162 (15.1) 1.000
Median tumour size (cm)# 6 (1.5-16.5) 4.8 (0–28) 0.176
Metastases at initial diagnosis    
  Lymph nodes 2 (4.4) 62 (5.8) 1.000
  Distant 5 (11.1) 87 (8.1) 0.423
Morphology    
  solitaire 9 (20) 319 (29.7) 0.324
  multifocal 36 (80) 749 (69.7) 0.565
  no data 0 6 (0.6) 1.000
BCLC at HCC diagnosis    
  BCLC A 9 (20) 258 (24) 0.727
  BCLC B 11 (24.4) 179 (16.7) 0.248
  BCLC C 19 (42.2) 458 (42.6) 1.000
  BCLC D 6 (13.3) 173 (16.1) 0.836
  no data 0 6 (0.6) 1.000
UICC    
  I 7 (15.6) 278 (25.9) 0.290
  II 11 (24.4) 320 (29.8) 0.629
  III 22 (48.9) 374 (34.8) 0.203
  VI 0 0 1.000
Primary therapy    
  Resection 8 (17.8) 213 (19.8) 1.000
  OLT 0 43 (4) 0.407
  OLT after bridging 2 (4.4) 188 (17.5) 0.054
  TACE 19 (42.2) 503 (46.8) 0.785
  RFA/PEI 2 (4.4) 55 (5.1) 1.000
  Chemotherapy 1 (2.2) 22 (2) 0.615
  Sorafenib 8 (17.8) 38 (3.5) <0.001
  Best supportive care 3 (6.7) 120 (11.2) 0.619
Overall survival (months)# 11.28 (0.7-127.6) 15.5 (0–131.3) 0.287
  1. #Data presented in (median [range]). A p value p<0.05 was considered significant and is marked in bold.